Modeling Impaired Judgement in Cocaine Abusers - 6

This study has been completed.
Sponsor:
Collaborator:
New York MDRU
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00015236
First received: April 18, 2001
Last updated: November 3, 2005
Last verified: June 1998
  Purpose

The purpose of this study is for the modeling of impaired judgement in cocaine abusers.


Condition Intervention Phase
Cocaine-Related Disorders
Substance-Related Disorders
Behavioral: Amantadine
Phase 4

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Prevention
Official Title: Modeling Impaired Judgement in Cocaine Abusers

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment: 0
Study Start Date: March 1997
Detailed Description:

The objective of this study is to investigate recognition memory and appreciation of changing contingencies in relation to a response judgement.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

(3 groups)Normal, healthy controls. Recent cocaine experience. Over 6 months since the last cocaine experience.

Exclusion Criteria:

Psychosis or mood disorder. History of seizure, head trauma

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00015236

Locations
United States, New York
New York MDRU
New York, New York, United States, 10010
Sponsors and Collaborators
New York MDRU
Investigators
Principal Investigator: John Rotrosen, M.D. New York MDRU
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00015236     History of Changes
Other Study ID Numbers: NIDA-5-0013-6, Y01-5-0013-6
Study First Received: April 18, 2001
Last Updated: November 3, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Amantadine
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Antiviral Agents
Anti-Infective Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on April 15, 2014